A phase I, open-label study to evaluate the safety and tolerability of recombinant HIV-1 vaccines in HIV-1 infected young adults with control of HIV-1 replication and on stable highly active antiretroviral therapy (HAART).
Latest Information Update: 18 Sep 2021
At a glance
- Drugs HIV vaccine (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- 18 May 2012 Biomarkers information updated
- 13 Feb 2012 Actual end date changed from Jul 2008 to Feb 2009 as reported by ClinicalTrials.gov.
- 13 Feb 2012 Actual patient number is 20 according to ClinicalTrials.gov.